Variations to national authorisations

1. Where do I send the Product information texts?

To ensure a simplified and uncomplicated communication between authorities and companies the entire text communication should be done via eService.

2. How much time is provided to respond to a letter of deficiency for a Type IA Variation? What is the procedure if the response is also incomplete?

If not all required documents, according to Classification Guideline, are enclosed, they will be requested by the Austrian competent authority.

Since these deficiencies are seen as “accidental incompleteness”, the completion of the submission should be done within 4 days.

If the submission is still not complete or incorrect, it will be rejected according to AVG (Austrian “allgemeines Verwaltungsverfahrensgesetz”) (see Q4 of EMA Q&A's).

3. How to classify changes in the pharmacovigilance system?

For authorised human medicinal products: Within the scope of Change of Ownership or when introducing a new summary of pharmacovigilance system, the summary must be submitted classified as a C.8.a variation. Later changes to QPPV or location of the PSMF are handled via the Article 57 database.

For authorised veterinary medicinal products: Within the scope of Change of Ownership or when introducing a new DDPS, the DDPS must be submitted classified as a C.II.7 variation. Other changes, e.g. change of QPPV, fall in the respective subcategory of variation C.I.9.

4. Do the requirements of the Medical Devices Ordinance also apply to registered medicinal specialities?

Does the medical device regulation (EU) 2017/745) must also be observed if, for example, eye drops in multi-dose containers (bottle - dropper - cap), nasal sprays in multi-dose containers (bottle - spray head/actuator - cap) are newly introduced or changed for registered speciality medicinal products?

Yes, further information can be found here: Medicinal product-medical device combinations

5. How are changes to registered medicinal products in combination with medical devices/components to be submitted?

If the packaging of a registered medicinal product is changed with regard to a medical device or medical device component (integral), this must be reported to the Federal Office for Safety in Health Care in accordance with Section 24 AMG. 
The same applies to referenced medical devices packaged together with the medicinal product.

Both when introducing a new medical device/component and when changing a medical device/component previously listed in the registration of the medicinal product, the relevant item in the form "Changes according to § 24 AMG as amended" must be completed. Corresponding additional information must be provided in sections 3.2 and 3.5.

Furthermore, the relevant documents must be enclosed or updated in the dossier (e.g. Module 3.2.R Medical Device, 3.2.P.7).

Email

Further inquiry note